IVA337, the leading drug candidate from the biopharmaceutical company Inventiva, received a prize at the recent 4th Systemic Sclerosis World Congress for its innovative character in treating systemic sclerosis. IVA337 is currently being tested in a Phase 2b clinical trial. At the congress, Inventiva researchers showed that IVA337 has…
After 6 years of infertility, suffering from pulmonary fibrosis (PF), 36-year-old Sonica was finally able to get pregant. Now almost 13 weeks into the pregnancy, she shares her experience. Learn about PF and keep updated on all the latest news here: http://bit.ly/1VElTQA…
This is the first of a series of videos created by the Juravinski Cancer Center in order to help patients with lung disease, as in the case of pulmonary fibrosis (PF), breathe better. Read more on PF and keep updated on all the latest news here: http://bit.ly/1VElTQA…
Mitophagy, a protective mechanism against mitochondria reactive oxygen species (ROS), in lung macrophages is a key mechanism underlying the development of pulmonary fibrosis, according to a study titled “Macrophage Akt1 Kinase-Mediated Mitophagy Modulates Apoptosis Resistance and Pulmonary Fibrosis,” and published in the journal Immunity. Alveolar macrophages,…
Prof. Vincent Cottin discusses the diseases which IPF is often confused with. For example, NSIP (non-specific interstitial pneumonia) because of similar imaging and clinical features between both diseases. Read more about idiopathic pulmonary fibrosis here: http://bit.ly/1QiRmr3…
BoehringerUS shared this video where you can see, with a true patient story, how it is to live with idiopathic pulmonary fibrosis (IPF). Watch the video to learn more about it and how pulmonary fibrosis patients caregivers deal with the disease. Learn…
Last week’s hot topic on pulmonary fibrosis was Country Music Star Joe Nichols Shares His Dad’s IPF Story in ‘Breathless,’ a Public Awareness Campaign written by Daniela Semedo. This article was about country music artist Joe Nichols partnering with Boehringer Ingelheim to raise awareness about idiopathic pulmonary…
Combined evidence from the TOMORROW and INPULSIS clinical trials confirms the safety and efficacy of OFEV (nintedanib, Boehringer Ingelheim) in slowing disease progression and greatly reducing acute exacerbations in patients with idiopathic pulmonary fibrosis (IPF), a study reported. The article detailing the pooled analyses of the clinical studies, “…
Learn more about pulmonary fibrosis here: http://bit.ly/1lfMsiZ Note: Pulmonary Fibrosis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always…
Get regular updates to your inbox.
